Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.

Lochmüller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogoryelova O, Woods C, Lai A, Shah J, Koutsoukos T, Skrinar A, Mansbach H, Kakkis E, Mozaffar T.

Neurology. 2019 Apr 30;92(18):e2109-e2117. doi: 10.1212/WNL.0000000000006932. Epub 2019 Jan 25.

2.

GNE genotype explains 20% of phenotypic variability in GNE myopathy.

Pogoryelova O, Wilson IJ, Mansbach H, Argov Z, Nishino I, Lochmüller H.

Neurol Genet. 2019 Feb 1;5(1):e308. doi: 10.1212/NXG.0000000000000308. eCollection 2019 Feb.

3.

Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion.

Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, Chan Y, Nafissi S, Shamshiri H, Kakkis E, Lochmüller H.

Neuromuscul Disord. 2018 Feb;28(2):158-168. doi: 10.1016/j.nmd.2017.11.001. Epub 2017 Nov 14.

4.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS.

Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3.

PMID:
28344102
5.

Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.

Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Theeuwes A, Beer TM, Tombal B, Ueda T.

Int J Urol. 2016 May;23(5):395-403. doi: 10.1111/iju.13072. Epub 2016 Mar 27.

6.

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B.

Eur Urol. 2016 Oct;70(4):675-683. doi: 10.1016/j.eururo.2016.03.017. Epub 2016 Mar 19.

PMID:
27006332
7.

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer TM, Tombal B.

Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14.

PMID:
25888263
8.

Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC).

Ivanescu C, Phung D, Loriot Y, Saad F, Mansbach H, Beer TM, Tombal B, Holmstrom S.

Value Health. 2014 Nov;17(7):A650-1. doi: 10.1016/j.jval.2014.08.2365. Epub 2014 Oct 26. No abstract available.

9.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

10.

Bioavailability of intranasal vs. rectal diazepam.

Ivaturi V, Kriel R, Brundage R, Loewen G, Mansbach H, Cloyd J.

Epilepsy Res. 2013 Feb;103(2-3):254-61. doi: 10.1016/j.eplepsyres.2012.07.018. Epub 2012 Sep 13.

PMID:
22981338
11.

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, Mansbach H, Nohria V; RESTORE 1/Study 301 Investigators.

Neurology. 2011 May 3;76(18):1555-63. doi: 10.1212/WNL.0b013e3182194bd3. Epub 2011 Mar 30.

PMID:
21451152
12.

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H; RESTORE 2 Study Group.

Neurology. 2010 Nov 16;75(20):1817-24. doi: 10.1212/WNL.0b013e3181fd6170. Epub 2010 Oct 13.

PMID:
20944074
13.

Comparison of rizatriptan and sumatriptan.

O'Quinn S, Mansbach H, Salonen R.

Headache. 1999 Jan;39(1):59-60. No abstract available.

PMID:
18567177
14.

Acute stroke units.

Dayno JM, Mansbach HH.

J Stroke Cerebrovasc Dis. 1999 May-Jun;8(3):160-70. No abstract available.

PMID:
17895159
15.

Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.

Tepper SJ, Dahlöf CG, Dowson A, Newman L, Mansbach H, Jones M, Pham B, Webster C, Salonen R.

Headache. 2004 Oct;44(9):856-64.

PMID:
15447694
16.

Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database.

Christoph-Diener H, Ferrari M, Mansbach H; SNAP Database Study Group.

Neurology. 2004 Aug 10;63(3):520-4.

PMID:
15304585
17.

The sumatriptan/naratriptan aggregated patient (SNAP) database: aggregation, validation and application.

Barrows C, Saunders W, Austin R, Putnam G, Mansbach H; SNAP Study Group.

Cephalalgia. 2004 Jul;24(7):586-95.

PMID:
15196301
18.

Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients.

Bruno A, McConnell JP, Mansbach HH 3rd, Cohen SN, Tietjen GE, Bang NU.

Stroke. 2002 Jan;33(1):57-60.

PMID:
11779889
19.

Comparison of rizatriptan and sumatriptan: a reply to Tfelt-Hansen et al.

O'Quinn S, Saiers J, Mansbach H, Putnam G, Salonen R.

Headache. 2000 Jul-Aug;40(7):605-9. No abstract available.

PMID:
10940103
20.

Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.

Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, Mansbach HH, Daley S, Schultz LR, Karanjia PN, Scott P, Dayno JM, Vereczkey-Porter K, Benesch C, Book D, Coplin WM, Dulli D, Levine SR.

Neurology. 1999 Jul 22;53(2):424-7.

PMID:
10430444
21.

Preliminary clinical-radiological assessment of a MR tissue signature model in human stroke.

D'Olhaberriague L, Welch KM, Nagesh V, Gymnopoulos C, Mansbach HH, Hugg JW, Boska MD, Knight RA, Schultz LR, Levine SR, Chopp M.

J Neurol Sci. 1998 Apr 1;156(2):158-66.

PMID:
9588851
22.

A reappraisal of reliability and validity studies in stroke.

D'Olhaberriague L, Litvan I, Mitsias P, Mansbach HH.

Stroke. 1996 Dec;27(12):2331-6. Review.

PMID:
8969803
23.

Differential expression of immediate early genes in the hippocampus in the kindling model of epilepsy.

Simonato M, Hosford DA, Labiner DM, Shin C, Mansbach HH, McNamara JO.

Brain Res Mol Brain Res. 1991 Sep;11(2):115-24.

PMID:
1661808
24.

Microinjection of a benzodiazepine into substantia nigra elevates kindled seizure threshold.

King PH, Shin C, Mansbach HH, Chen LS, McNamara JO.

Brain Res. 1987 Oct 13;423(1-2):261-8.

PMID:
3315121

Supplemental Content

Loading ...
Support Center